Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer
Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Personalized medicine remains an unmet need in ovarian cancer due to its heterogeneous nature and complex immune microenvironments, which has gained increasing attention in the era of immunotherapy. A key obstacle is the lack of reliable biomarkers to identify patients who would benefit significantly from the therapy. While conventional clinicopath...
Alternative Titles
Full title
Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dcec9745b253488197c0a913f1f8b1e2
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dcec9745b253488197c0a913f1f8b1e2
Other Identifiers
ISSN
1757-2215
E-ISSN
1757-2215
DOI
10.1186/s13048-024-01518-w
